Halozyme Therapeutics has entered into a worldwide collaboration and license agreement with Pfizer to develop and commercialize products combining Pfizer biologics with Halozyme’s Enhanze technology. Enhanze is based on the Halozyme’s recombinant human hyaluronidase enzyme (rHuPH20).   Pfizer has a worldwide license to develop and commercialize products combining rHuPH20 with its biologics for as many as six targets. Halozyme will receive an initial payment of $8 million, which includes an upfro...